Respiratory syncytial virus (RSV)

espiratory Syncytial Virus (RSV) poses a significant global health threat to infants and young children. It is a primary cause of hospitalization due to severe respiratory illnesses such as bronchiolitis and pneumonia. While most children experience mild cold-like symptoms, certain high-risk populations preterm infants, and those with congenital heart or lung conditions—are especially vulnerable to severe RSV infections, often requiring hospitalization and intensive care.

In the absence of a safe and effective vaccine, alternative prophylactic strategies have been developed to protect these vulnerable populations.

Monoclonal Antibodies: A Breakthrough in RSV Prevention

Monoclonal antibodies (mAbs) have emerged as a cornerstone in the prevention of RSV infections among high-risk infants. Among them, Palivizumab, a humanized monoclonal antibody targeting the RSV F protein, has been widely used.

Palivizumab is typically administered monthly during the RSV season, and studies have shown that it can reduce hospitalization rates by approximately 55% in preterm infants without chronic lung disease (Groothuis & Nishida, 2002). Its mechanism involves neutralizing the RSV virus, preventing it from entering lung cells and causing severe infection.

Despite its proven efficacy, Palivizumab has some limitations:

  • Monthly injections can be labor-intensive for caregivers and healthcare providers.
  • Protection is not uniform across all high-risk populations (Homaira et al., 2014).

Next-Generation Monoclonal Antibodies: Nirsevimab

Recent advances in antibody engineering have introduced next-generation mAbs, such as Nirsevimab, designed to offer extended protection with a single dose per RSV season.

Nirsevimab also targets the RSV F protein but has enhanced binding efficacy and prolonged half-life, significantly reducing the frequency of administration compared to Palivizumab (Bergeron & Tripp, 2021). Clinical trials indicate that Nirsevimab may broaden protection to include both preterm and full-term infants, potentially becoming the new standard for RSV prophylaxis (Bergeron & Tripp, 2021).

Efficacy in High-Risk Populations

Both Palivizumab and Nirsevimab demonstrate substantial reductions in RSV-related hospitalizations, particularly among preterm infants. However, further research is necessary to evaluate:

  • Protective effects in other high-risk groups, such as children with Down syndrome or cystic fibrosis.
  • Long-term outcomes, including RSV immunity and durability of protection across multiple RSV seasons (Homaira et al., 2014).

Future Perspectives

Advances in understanding RSV pathogenesis and the corresponding immune responses are guiding the development of more efficient, less labor-intensive prophylactic options. While monoclonal antibodies remain critical for protecting high-risk infants today, the ultimate goal is the development of a safe, effective RSV vaccine that can provide broader and more sustainable protection for all children worldwide.

Conclusion

Monoclonal antibodies play a vital role in managing RSV infections in high-risk infants and children. The advent of next-generation mAbs like Nirsevimab promises enhanced protection and simplified administration, representing a major step forward in RSV prevention. As research progresses, these therapies bridge the gap until vaccines capable of providing universal, long-term protection become widely available.

References

  1. Groothuis, J. R., & Nishida, H. (2002). Palivizumab prophylaxis in preterm infants and infants with chronic lung disease. Pediatrics, 110(6), e71.
  2. Homaira, N., Oei, J., et al. (2014). Effectiveness of palivizumab in high-risk infants: a systematic review. Journal of Paediatrics and Child Health, 50(10), 801–810.
  3. Bergeron, J. R., & Tripp, R. A. (2021). Next-generation monoclonal antibodies for RSV prevention: Nirsevimab and beyond. Current Opinion in Virology, 49, 10–17.